Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, open-label, multicenter phase II study investigating the
advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung
cancer (ALK+ NSCLC) patients by deep phenotyping
Phase:
Phase 2
Details
Lead Sponsor:
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest